What Is Adaptive Biotechnologies Corpor (ADPT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Adaptive Biotechnologies Corpor's intrinsic value is estimated at $3.85, suggesting the stock is overvalued at its current price of $21.02. With 12 out of 13 models flagging downside (-81.7% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $20.93 (-0.4%), while First Chicago — the most conservative — estimates $0.22 (-98.9%). This +98.5% gap reflects genuine analytical uncertainty about Adaptive Biotechnologies Corpor's intrinsic worth. Among models with highest confidence, Markov DDM lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About ADPT?
13 of 13 models are currently active for ADPT. All 13 active models suggest the stock trades above fair value. The Bayesian DCF estimates ADPT's intrinsic value at $2.35, implying -88.8% downside from the current price. See which stocks rank higher →
How Does ADPT Rank in Diagnostics & Research?
Among 3 Diagnostics & Research stocks, ADPT ranks #2 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.
As a pharmaceutical industry, Adaptive Biotechnologies Corpor operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ADPT should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ADPT a Value Trap?
CirclFi's Value Trap algorithm assigns ADPT a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Adaptive Biotechnologies Corpor. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Adaptive Biotechnologies Corpor's fundamental quality profile registers 7.5/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +98.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ADPT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ADPT's 13 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad